Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).

Fiche publication

Date publication

novembre 2015


Cancer chemotherapy and pharmacology


Membres identifiés du Cancéropôle Est :

Tous les auteurs :
You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G


Relationships between pharmacokinetic (PK) parameters of etoposide and toxicity survivals were reported in cancer patients treated at standard doses. The clinical impact of PK variations of etoposide high doses has never been explored in lymphoma patients.

Mots clés

Adult, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Bilirubin, blood, Carmustine, administration & dosage, Creatinine, blood, Cytarabine, administration & dosage, Disease-Free Survival, Etoposide, administration & dosage, Female, Hodgkin Disease, drug therapy, Humans, Kaplan-Meier Estimate, Lymphoma, Non-Hodgkin, drug therapy, Male, Melphalan, administration & dosage, Middle Aged, Peripheral Blood Stem Cell Transplantation, Prognosis, Proportional Hazards Models, Prospective Studies, Risk Assessment, Serum Albumin, analysis, Transplantation, Autologous, Treatment Outcome, Young Adult


Cancer Chemother. Pharmacol.. 2015 Nov;76(5):939-48